{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T06:21:00Z","timestamp":1763706060548,"version":"3.37.3"},"reference-count":23,"publisher":"The Journal of Rheumatology","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Psoriatic arthritis (PsA) substantially impairs quality of life. Clinical trials generally focus on polyarticular PsA, but less is known about the assessment and management of oligoarticular and moderate PsA. An online survey was conducted to determine Canadian rheumatologists\u2019 perspectives on the definition and treatment of oligoarticular and moderate PsA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Regional and national experts treating patients with PsA were asked to complete an online survey to assess their approach to identifying and managing patients with PsA. Survey questions were developed based on guidance from a committee of Canadian rheumatologists.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Sixty-four of 78 rheumatologists responded, representing 6 major Canadian provinces. Nearly half of respondents were in practice &gt; 20 years. The majority of rheumatologists reported using swollen joint count (SJC) to describe moderate PsA (86.4%) and oligoarticular PsA (96.7%), and considered location of inflammation in PsA assessments. SJC cutoff scores for reporting moderate PsA varied among rheumatologists, suggesting lack of an agreed-upon definition for moderate PsA. Sixty-eight percent of rheumatologists identified access to treatment as the greatest challenge with oligoarticular PsA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>According to the surveyed rheumatologists, SJC remains a key assessment variable when defining oligoarticular and moderate PsA. Although the number of joints is considered when determining the effect of PsA on patients, joint location and functional impairment are also considered when describing the disease as moderate. Access to treatment for patients with &lt; 5 affected joints is challenging.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.201195","type":"journal-article","created":{"date-parts":[[2021,5,15]],"date-time":"2021-05-15T12:20:25Z","timestamp":1621081225000},"page":"1692-1697","source":"Crossref","is-referenced-by-count":3,"title":["Canadian Rheumatologists\u2019 Perspectives on Moderate Psoriatic Arthritis and Oligoarticular Psoriatic Arthritis"],"prefix":"10.3899","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9074-0592","authenticated-orcid":false,"given":"Dafna D.","family":"Gladman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Starr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7948-7960","authenticated-orcid":false,"given":"Alfred","family":"Cividino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Julie","family":"Gaudreau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Jelley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denise","family":"Nicholson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3960-4082","authenticated-orcid":false,"given":"Jacob","family":"Karsh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2262","published-online":{"date-parts":[[2021,5,15]]},"reference":[{"key":"2022062114101786000_48.11.1692.1","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s40744-016-0029-z","article-title":"Psoriatic arthritis and burden of disease: patient perspectives from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) survey","volume":"3","author":"Kavanaugh","year":"2016","journal-title":"Rheumatol Ther"},{"key":"2022062114101786000_48.11.1692.2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200104)45:2<151::AID-ANR168>3.0.CO;2-T"},{"key":"2022062114101786000_48.11.1692.3","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12190"},{"key":"2022062114101786000_48.11.1692.4","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.110278"},{"key":"2022062114101786000_48.11.1692.5","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1002\/art.37939","article-title":"Reduced joint counts misclassify patients with oligoarticular psoriatic arthritis and miss significant numbers of patients with active disease","volume":"65","author":"Coates","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2022062114101786000_48.11.1692.6","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.181089"},{"key":"2022062114101786000_48.11.1692.7","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20162"},{"key":"2022062114101786000_48.11.1692.8","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s40744-018-0115-5","article-title":"Oligoarticular psoriatic arthritis: addressing clinical challenges in an intriguing phenotype","volume":"5","author":"Marchesoni","year":"2018","journal-title":"Rheumatology Ther"},{"key":"2022062114101786000_48.11.1692.9","first-page":"679","article-title":"Patients with psoriatic arthritis and oligoarthritic subtype report higher disease burden than patients with a polyarthritic pattern \u2013 data from the German collaborative arthritis centres [abstract]","volume":"67","author":"Huscher","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2022062114101786000_48.11.1692.10","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.39573","article-title":"Group for Research and Assessment of Psoriasis and Psoriatic Arthritis: treatment recommendations for psoriatic arthritis 2015","volume":"68","author":"Coates","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2022062114101786000_48.11.1692.11","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/acr.23789","article-title":"Special article: 2018 American College of Rheumatology\/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis","volume":"71","author":"Singh","year":"2019","journal-title":"Arthritis Care Res"},{"key":"2022062114101786000_48.11.1692.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.12.018"},{"key":"2022062114101786000_48.11.1692.13","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.032482"},{"key":"2022062114101786000_48.11.1692.14","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200304070-00001"},{"key":"2022062114101786000_48.11.1692.15","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217159"},{"key":"2022062114101786000_48.11.1692.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1505557"},{"key":"2022062114101786000_48.11.1692.17","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1001\/jamadermatol.2013.5264","article-title":"Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003-2011","volume":"149","author":"Armstrong","year":"2013","journal-title":"JAMA Dermatol"},{"key":"2022062114101786000_48.11.1692.18","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13150"},{"key":"2022062114101786000_48.11.1692.19","unstructured":"Ontario Ministry of Health . Exceptional access program reimbursement criteria for frequently requested drugs. February 1, 2021. [Internet. Accessed June 1, 2021.] Available from: www.health.gov.on.ca\/en\/pro\/programs\/drugs\/docs\/frequently_requested_drugs.pdf"},{"key":"2022062114101786000_48.11.1692.20","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.030783"},{"key":"2022062114101786000_48.11.1692.21","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207507"},{"key":"2022062114101786000_48.11.1692.22","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.140172"},{"key":"2022062114101786000_48.11.1692.23","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211137"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.201195","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T19:40:45Z","timestamp":1699040445000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.201195"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,15]]},"references-count":23,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,11,1]]},"published-print":{"date-parts":[[2021,11]]}},"alternative-id":["10.3899\/jrheum.201195"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.201195","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"type":"print","value":"0315-162X"},{"type":"electronic","value":"1499-2752"}],"subject":[],"published":{"date-parts":[[2021,5,15]]}}}